Current status of antiplatelet agents to prevent stroke

Current Neurology and Neuroscience Reports

Volumn 11, Issue 1, 2011, Pages 6-14

  Field, Thalia S ^b   Benavente, Oscar R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiplatelet; Aspirin; Aspirin failure; Cardioembolic; Clopidogrel; Clopidogrel resistance; Dipyridamole; Prevention; Stroke; TIA; Trial; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 2C19; DIPYRIDAMOLE; HEMOSIDERIN; OMEPRAZOLE; PLACEBO; SARPOGRELATE; SIMVASTATIN; TRIFLUSAL; WARFARIN;

ARTICLE; ASPIRIN RESISTANCE; BLEEDING; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBRAL MICROBLEEDING; CLOPIDOGREL RESISTANCE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESISTANCE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEUKOARAIOSIS; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; PATIENT COMPLIANCE; RISK REDUCTION; SECONDARY PREVENTION; STOMACH DISEASE; THROMBOCYTE AGGREGATION; TRANSIENT ISCHEMIC ATTACK;

ASPIRIN; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS; STROKE; TICLOPIDINE;

EID: 79551527287     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-010-0162-y     Document Type: Article

References (50)

1. GA Donnan M Fisher M Macleod SM Davis 2008 Stroke The Lancet 371 9624 1612 23 1:CAS:528:DC%2BD1cXlslWhsbY%3D 10.1016/S0140-6736(08)60694-7 This article provides an overview of stroke, including epidemiology, diagnosis, and therapeutics (Pubitemid 351626845)
2. W Rosamond K Flegal G Friday, et al. 2007 Heart Disease and Stroke Statistics-2007 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 115 5 e69 171 10.1161/CIRCULATIONAHA.106.179918 17194875 (Pubitemid 46226160)
3. SC Johnston PM Rothwell MN Nguyen-Huynh, et al. 2007 Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack Lancet 369 9558 283 92 10.1016/S0140-6736(07)60150-0 17258668 This article presents the validation of the ABCD TIA score. This score is the most commonly use to stratify and manage TIA patients (Pubitemid 46136488)
4. PM Rothwell MF Giles A Chandratheva, et al. 2007 Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison Lancet 370 9596 1432 42 10.1016/S0140-6736(07)61448-2 17928046 This is influential paper demonstrating the importance of initiating early and multimodal stroke prevention strategies in TIA patients (Pubitemid 47576154)
5. E Touze O Varenne G Chatellier, et al. 2005 Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis Stroke 36 12 2748 55 10.1161/01.STR. 0000190118.02275.33 16254218
6. SS Group 1997 A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin Annals of Neurology 42 6 857 65 10.1002/ana.410420606 (Pubitemid 28008415)
7. JP Mohr JLP Thompson RM Lazar, et al. 2001 A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke N Engl J Med. 345 20 1444 51 1:CAS:528:DC%2BD3MXovVaqsrc%3D 10.1056/NEJMoa011258 11794192
8. A Algra 2007 Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): A randomised controlled trial The Lancet Neurology. 6 2 115 24 10.1016/S1474-4422(06)70685-8 (Pubitemid 46097527)
9. MI Chimowitz MJ Lynn H Howlett-Smith, et al. 2005 Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis N Engl J Med. 352 13 1305 16 1:CAS:528:DC%2BD2MXislCjsLo%3D 10.1056/NEJMoa043033 15800226 (Pubitemid 40411497)
10. Antithrombotic Trialists C 2009 Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials The Lancet 373 9678 1849 60 10.1016/S0140-6736(09)60503-1 This is an updated systematic review and meta-analysis of all antiplatelet trials
11. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. The New England Journal of Medicine. 1991;325(18):1261-6.
12. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet. 1991;338(8779):1345-9.
13. AT Collaboration 2002 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ. 324 7329 71 86 10.1136/bmj.324.7329.71
14. HC Diener L Cunha C Forbes, et al. 1996 European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke Journal of the Neurological Sciences. 143 1-2 1 13 1:CAS:528: DyaK2sXisFOktQ%3D%3D 10.1016/S0022-510X(96)00308-5 8981292 (Pubitemid 26402780)
15. PC Sze D Reitman MM Pincus, et al. 1988 Antiplatelet agents in the secondary prevention of stroke: meta- analysis of the randomized control trials Stroke. 19 4 436 42 1:STN:280:DyaL1c3gsFCjtA%3D%3D 3284017
16. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. The Lancet. 2006;367(9523):1665-73.
17. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet. 1996;348(9038):1329-39.
18. RL Sacco HC Diener S Yusuf, et al. 2008 Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke N Engl J Med. 359 12 1238 51 1:CAS:528:DC%2BD1cXhtFGjurjF 10.1056/NEJMoa0805002 18753638
19. SR Mehta S Yusuf RJG Peters, et al. 2001 Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study The Lancet. 358 9281 527 33 1:CAS:528:DC%2BD3MXmtV2ht7g%3D 10.1016/S0140-6736(01)05701-4 (Pubitemid 32772726)
20. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial I. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N Engl J Med. 2001;345(7):494-502.
21. SR Steinhubl PB Berger JT Mann 3rd, et al. 2002 Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA. 288 19 2411 20 1:CAS:528:DC%2BD38XoslOksL0%3D 10.1001/jama.288.19.2411 12435254 (Pubitemid 35340537)
22. PH-C Diener PJ Bogousslavsky PLM Brass, et al. 2004 Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial The Lancet. 364 9431 331 7 1:CAS:528:DC%2BD2cXmtVSktbs%3D 10.1016/S0140-6736(04)16721-4 (Pubitemid 38970009)
23. DL Bhatt KAA Fox W Hacke, et al. 2006 Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events N Engl J Med. 354 16 1706 17 1:CAS:528:DC%2BD28Xjs12gsLk%3D 10.1056/NEJMoa060989 16531616
24. J Kennedy MD Hill KJ Ryckborst, et al. 2007 Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial The Lancet Neurology. 6 11 961 9 1:CAS:528: DC%2BD2sXhtlCgsrbO 10.1016/S1474-4422(07)70250-8 (Pubitemid 47562312)
25. GJ Hankey J Costa JM Ferro, et al. 2006 Triflusal for Preventing Serious Vascular Events in People at High Risk Stroke. 37 8 2193 5 10.1161/01.STR. 0000231642.59626.74 (Pubitemid 44309929)
26. F Gotoh H Tohgi S Hirai, et al. 2000 Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction Journal of Stroke and Cerebrovascular Diseases. 9 4 147 57 10.1053/jscd.2000.7216 (Pubitemid 30480490)
27. Y Huang Y Cheng J Wu, et al. 2008 Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study The Lancet Neurology. 7 6 494 9 1:CAS:528:DC%2BD1cXntlSjtLo%3D 10.1016/S1474-4422(08)70094- 2
28. Y Shinohara K Nishimaru T Sawada, et al. 2008 Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial Stroke. 39 6 1827 33 1:CAS:528:DC%2BD1cXlvFaisbw%3D 10.1161/STROKEAHA.107. 505131 18388340
29. RG Hart LA Pearce MI Aguilar 2007 Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation Annals of Internal Medicine. 146 12 857 67 17577005
30. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. The Lancet. 2006;367(9526):1903-12.
31. SJ Connolly J Pogue RG Hart, et al. 2009 Effect of clopidogrel added to aspirin in patients with atrial fibrillation N Engl J Med. 360 20 2066 78 10.1056/NEJMoa0901301 19336502
32. NM Bornstein VG Karepov BD Aronovich, et al. 1994 Failure of aspirin treatment after stroke Stroke. 25 2 275 7 1:STN:280:DyaK2c7jsFOlsw%3D%3D 8303730
33. CM Helgason KM Bolin JA Hoff, et al. 1994 Development of aspirin resistance in persons with previous ischemic stroke Stroke. 25 12 2331 6 1:STN:280:DyaK2M%2FmsVyqtg%3D%3D 7974569
34. K Andersen M Hurlen H Arnesen I Seljeflot 2002 Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease Thromb Res. 108 1 37 42 10.1016/S0049-3848(02)00405-X 12586130 (Pubitemid 36197660)
35. JA Cambria-Kiely PJ Gandhi 2002 Aspirin resistance and genetic polymorphisms J Thromb Thrombolysis. 14 1 51 8 1:CAS:528:DC%2BD3sXkvFehtQ%3D%3D 10.1023/A:1022066305399 12652150 (Pubitemid 36277691)
36. S Sanderson J Emery T Baglin AL Kinmonth 2005 Narrative review: aspirin resistance and its clinical implications Ann Intern Med. 142 5 370 80 1:CAS:528:DC%2BD2MXktFSjsLs%3D 15738456
37. PA Gum K Kottke-Marchant ED Poggio, et al. 2001 Profile and prevalence of aspirin resistance in patients with cardiovascular disease Am J Cardiol. 88 3 230 5 1:CAS:528:DC%2BD3MXltlOjurc%3D 10.1016/S0002-9149(01)01631-9 11472699 (Pubitemid 32721947)
38. PA Gum K Kottke-Marchant PA Welsh, et al. 2003 A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol. 41 6 961 5 1:CAS:528: DC%2BD3sXislejsLo%3D 10.1016/S0735-1097(02)03014-0 12651041 (Pubitemid 36315537)
39. MR Mueller A Salat P Stangl, et al. 1997 Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty Thromb Haemost. 78 3 1003 7 1:CAS:528: DyaK2sXmtVejs74%3D 9308744
40. TA Nguyen JG Diodati C Pharand 2005 Resistance to clopidogrel: a review of the evidence J Am Coll Cardiol. 45 8 1157 64 1:CAS:528:DC%2BD2MXjtlagsb8%3D 10.1016/j.jacc.2005.01.034 15837243 (Pubitemid 40523131)
41. JP Sugunaraj C Palaniswamy DR Selvaraj, et al. 2010 Clopidogrel resistance Am J Ther. 17 2 210 5 10.1097/MJT.0b013e3181bdc3e4 19829090
42. AR Shuldiner JR O'Connell KP Bliden, et al. 2009 Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA. 302 8 849 57 1:CAS:528:DC%2BD1MXhtVCnt7zL 10.1001/jama.2009.1232 19706858
43. G Pare SR Mehta S Yusuf, et al. 2010 Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med. 363 18 1704 14 1:CAS:528:DC%2BC3cXhtlKitL%2FP 10.1056/NEJMoa1008410 20979470
44. F Fazekas R Kleinert G Roob, et al. 1999 Histopathologic analysis of foci of signal loss on gradient-echo T2-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds AJNR Am J Neuroradiol. 20 4 637 42 1:STN:280:DyaK1M3ltFKqsQ%3D%3D 10319975
45. H Kato M Izumiyama K Izumiyama, et al. 2002 Silent cerebral microbleeds on T2-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis Stroke. 33 6 1536 40 10.1161/01.STR.0000018012.65108.86 12052987 (Pubitemid 34619953)
46. T Imaizumi Y Horita M Chiba, et al. 2004 Dot-like hemosiderin spots on gradient echo T2-weighted magnetic resonance imaging are associated with past history of small vessel disease in patients with intracerebral hemorrhage J Neuroimaging. 14 3 251 7 15228767
47. YH Fan L Zhang WW Lam, et al. 2003 Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke Stroke. 34 10 2459 62 10.1161/01.STR.0000090841.90286.81 12958325 (Pubitemid 37221963)
48. SM Greenberg JA Eng M Ning, et al. 2004 Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage Stroke. 35 6 1415 20 10.1161/01.STR.0000126807.69758.0e 15073385 (Pubitemid 38697468)
49. KS Wong YL Chan JY Liu, et al. 2003 Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages Neurology. 60 3 511 3 1:STN:280:DC%2BD3s%2FmvV2qsg%3D%3D 12578941
50. Furie KL, Kasner SE, Adams RJ, et al.: Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2010 Oct 21. A task force of physicians reviews the most relevant data for secondary stroke prevention. This paper provides the most influential evidence-based guidelines to manage patients with prior stroke or TIA.